The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, United Therapeutics Corp (NASDAQ: UTHR) closed at $283.35 down -0.98% from its previous closing price of $286.14. In other words, the price has decreased by -$0.98 from its previous closing price. On the day, 0.56 million shares were traded.
Ratios:
For a deeper understanding of United Therapeutics Corp’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 3.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 11.35. For the most recent quarter (mrq), Quick Ratio is recorded 5.23 and its Current Ratio is at 5.46. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on June 02, 2025, initiated with a Overweight rating and assigned the stock a target price of $405.
BofA Securities Upgraded its Underperform to Neutral on April 21, 2025, while the target price for the stock was maintained at $314.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Jun 12 ’25 when PAUL MAHON bought 11,000 shares for $279.96 per share.
EDGEMOND JAMES sold 12,000 shares of UTHR for $3,904,496 on Jun 09 ’25. The CFO AND TREASURER now owns 8,118 shares after completing the transaction at $325.37 per share. On Jun 02 ’25, another insider, EDGEMOND JAMES, who serves as the CFO AND TREASURER of the company, sold 12,000 shares for $325.82 each. As a result, the insider received 3,909,893 and left with 8,118 shares of the company.
Valuation Measures:
As of this moment, United’s Price-to-Earnings (P/E) ratio for their current fiscal year is 11.31, and their Forward P/E ratio for the next fiscal year is 9.63. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.82. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.27 while its Price-to-Book (P/B) ratio in mrq is 1.88.
Stock Price History:
Over the past 52 weeks, UTHR has reached a high of $417.82, while it has fallen to a 52-week low of $266.98. The 50-Day Moving Average of the stock is -5.76%, while the 200-Day Moving Average is calculated to be -16.88%.
Shares Statistics:
A total of 45.07M shares are outstanding, with a floating share count of 43.99M. Insiders hold about 2.49% of the company’s shares, while institutions hold 99.56% stake in the company.
Earnings Estimates
The dynamic stock of United Therapeutics Corp (UTHR) is currently being evaluated by a team of 11.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $7.34, with high estimates of $8.6 and low estimates of $5.98.
Analysts are recommending an EPS of between $29.96 and $24.64 for the fiscal current year, implying an average EPS of $27.63. EPS for the following year is $28.43, with 13.0 analysts recommending between $31.4 and $22.75.
Revenue Estimates
A total of 11 analysts believe the company’s revenue will be $802.13M this quarter.It ranges from a high estimate of $827.3M to a low estimate of $757.41M. As of the current estimate, United Therapeutics Corp’s year-ago sales were $714.9MFor the next quarter, 11 analysts are estimating revenue of $831.58M. There is a high estimate of $936M for the next quarter, whereas the lowest estimate is $785.55M.
A total of 14 analysts have provided revenue estimates for UTHR’s current fiscal year. The highest revenue estimate was $3.37B, while the lowest revenue estimate was $3.07B, resulting in an average revenue estimate of $3.22B. In the same quarter a year ago, actual revenue was $2.88BBased on 14 analysts’ estimates, the company’s revenue will be $3.42B in the next fiscal year. The high estimate is $3.6B and the low estimate is $3.06B.
